Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 4.06
CEMP's Cash to Debt is ranked higher than
64% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CEMP: 4.06 )
CEMP' s 10-Year Cash to Debt Range
Min: 1.12   Max: No Debt
Current: 4.06

Equity to Asset 0.48
CEMP's Equity to Asset is ranked higher than
61% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CEMP: 0.48 )
CEMP' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.81
Current: 0.48

0.48
0.81
F-Score: 3
Z-Score: 2.11
M-Score: -1.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -400.05
CEMP's Operating margin (%) is ranked higher than
62% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. CEMP: -400.05 )
CEMP' s 10-Year Operating margin (%) Range
Min: -549.34   Max: -549.34
Current: -400.05

Net-margin (%) -415.57
CEMP's Net-margin (%) is ranked higher than
61% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. CEMP: -415.57 )
CEMP' s 10-Year Net-margin (%) Range
Min: -576.41   Max: -576.41
Current: -415.57

ROE (%) -106.97
CEMP's ROE (%) is ranked higher than
58% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. CEMP: -106.97 )
CEMP' s 10-Year ROE (%) Range
Min: -70.51   Max: -70.51
Current: -106.97

ROA (%) -68.20
CEMP's ROA (%) is ranked higher than
59% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. CEMP: -68.20 )
CEMP' s 10-Year ROA (%) Range
Min: -191.64   Max: -53.06
Current: -68.2

-191.64
-53.06
ROC (Joel Greenblatt) (%) -47199.84
CEMP's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. CEMP: -47199.84 )
CEMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -47425.41   Max: -18211.5
Current: -47199.84

-47425.41
-18211.5
» CEMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CEMP Guru Trades in Q2 2013

Jean-Marie Eveillard 1,308,701 sh (New)
» More
Q3 2013

CEMP Guru Trades in Q3 2013

Jean-Marie Eveillard 1,308,701 sh (unchged)
» More
Q4 2013

CEMP Guru Trades in Q4 2013

Jean-Marie Eveillard 780,275 sh (-40.38%)
» More
Q1 2014

CEMP Guru Trades in Q1 2014

Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CEMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Sold Out 0.03%$11.01 - $14.92 $ 14.5417%0
Jean-Marie Eveillard 2013-12-31 Reduce -40.38%0.02%$10.1 - $13.5 $ 14.5420%780275
Jean-Marie Eveillard 2013-06-30 New Buy0.03%$6.03 - $8.13 $ 14.54110%1308701
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.90
CEMP's P/B is ranked higher than
63% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. CEMP: 12.90 )
CEMP' s 10-Year P/B Range
Min: 2.35   Max: 12.9
Current: 12.9

2.35
12.9
P/S 33.00
CEMP's P/S is ranked higher than
74% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. CEMP: 33.00 )
CEMP' s 10-Year P/S Range
Min: 22.55   Max: 61.57
Current: 33

22.55
61.57
EV-to-EBIT -7.44
CEMP's EV-to-EBIT is ranked higher than
51% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CEMP: -7.44 )
CEMP' s 10-Year EV-to-EBIT Range
Min: -10.1   Max: -3.1
Current: -7.44

-10.1
-3.1
Current Ratio 5.36
CEMP's Current Ratio is ranked higher than
75% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CEMP: 5.36 )
CEMP' s 10-Year Current Ratio Range
Min: 2.48   Max: 30.34
Current: 5.36

2.48
30.34
Quick Ratio 5.36
CEMP's Quick Ratio is ranked higher than
77% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. CEMP: 5.36 )
CEMP' s 10-Year Quick Ratio Range
Min: 2.48   Max: 30.34
Current: 5.36

2.48
30.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.00
CEMP's Price/Net Cash is ranked higher than
79% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. CEMP: 16.00 )
CEMP' s 10-Year Price/Net Cash Range
Min: 2.64   Max: 11.87
Current: 16

2.64
11.87
Price/Net Current Asset Value 14.70
CEMP's Price/Net Current Asset Value is ranked higher than
78% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. CEMP: 14.70 )
CEMP' s 10-Year Price/Net Current Asset Value Range
Min: 2.63   Max: 10.91
Current: 14.7

2.63
10.91
Price/Tangible Book 12.90
CEMP's Price/Tangible Book is ranked higher than
69% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. CEMP: 12.90 )
CEMP' s 10-Year Price/Tangible Book Range
Min: 2.61   Max: 9.56
Current: 12.9

2.61
9.56
Price/Median PS Value 0.80
CEMP's Price/Median PS Value is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. CEMP: 0.80 )
CEMP' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 1.29
Current: 0.8

0.58
1.29
Earnings Yield (Greenblatt) -12.80
CEMP's Earnings Yield (Greenblatt) is ranked higher than
63% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. CEMP: -12.80 )
CEMP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -12.8   Max: 0
Current: -12.8

-12.8
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:9C1.Germany
Cempra Inc is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. The Company is a clinical-stage pharmaceutical company which is engaged in the development of differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's main product, solithromycin (CEM-101), is in Phase 3 clinical trials. The Company is developing solithromycin in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP. Solithromycin is a potent new fourth generation macrolide and the first fluoroketolide in clinical development. The Company is also completed a Phase 2 study of solithromycin in uncomplicated gonorrhea. Its second program is Taksta, which the Company is developing in the U.S. as a long term oral treatment for prosthetic joint infections caused by staphylococci, including S. aureus and MRSA. The Company is conducting a Phase 2 trial for Taksta in patients with prosthetic joint infections and have submitted a proposal for a Phase 3 trial for Tasksta as a treatment for PJI. The Company has licensed solithromycin to Toyama Chemical Co., Ltd. for development and commercialization in Japan while retaining the rights to the rest of the world. The Company is developing Taksta in the U.S. as a long term oral treatment of prosthetic joint infections, or PJI, caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus, or MRSA.
» More Articles for CEMP

Headlines

Articles On GuruFocus.com
No related article found.

More From Our Partners
US Stock Futures Flat; Fed Minutes In Focus Nov 19 2014 - BENZINGA

More From Other Websites
CEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Nov 19 2014
Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies Nov 19 2014
Cempra to Present at Two Upcoming Investor Conferences Nov 10 2014
Cempra to Present at Two Upcoming Investor Conferences Nov 10 2014
Moving Average Crossover Alert: Cempra (CEMP) Nov 06 2014
Why Cempra (CEMP) Could Be Positioned for a Surge? Nov 06 2014
CEMPRA, INC. Financials Nov 05 2014
Moving Average Crossover Alert: Cempra (CEMP) Nov 04 2014
Strength Seen in Cempra (CEMP): Stock Rises 10.1% Oct 31 2014
Cempra tops Street 3Q forecasts Oct 30 2014
Cempra tops Street 3Q forecasts Oct 30 2014
Cempra to Report Third Quarter 2014 Financial Results and Host Webcast and Conference Call on... Oct 29 2014
Cempra Reports Third Quarter 2014 Financial Results and Provides Corporate Update Oct 29 2014
CEMPRA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 29 2014
CEMPRA, INC. Files SEC form 10-Q, Quarterly Report Oct 29 2014
Cempra Reports Third Quarter 2014 Financial Results and Provides Corporate Update Oct 29 2014
Q3 2014 Cempra Inc Earnings Release - After Market Close Oct 29 2014
Cempra to Report Third Quarter 2014 Financial Results and Host Webcast and Conference Call on... Oct 22 2014
CEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Oct 17 2014
Tetraphase (TTPH) Crumbles: Stock Tanks by 15% Oct 17 2014
PTC Therapeutics (PTCT) Crumbles: Stock Falls by 5.5% Oct 13 2014
Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session Oct 13 2014
NanoViricides, Inc. (NNVC) in Focus: Stock Jumps 9.9% Oct 06 2014
Esperion Therapeutics (ESPR) in Focus: Stock Jumps 5.1% Oct 06 2014
Durata Therapeutics, Inc. (DRTX) Surges: Stock Rises 17.3% Oct 06 2014
Alcobra (ADHD) Crumbles: Stock Falls by 7.4% Oct 06 2014
Cempra to Present Late-Breaker on Solithromycin Reducing Inflammation in an Animal Model for Cancer... Mar 27 2014
Cempra, Inc. Reports Fourth Quarter and Full Year 2013 Financial and Operating Results Feb 27 2014
Cempra, Inc. to Report Fourth Quarter and Full Year 2013 Financial and Operating Results, and Host... Feb 25 2014
Cempra Initiates Solithromycin Pediatric Program Feb 20 2014
Cempra's Solithromycin Demonstrates No QT Effects in Thorough QT Study Feb 12 2014
Cempra, Inc. to Present at BIO CEO & Investor Conference and 2014 Leerink Global Healthcare... Feb 04 2014
Cempra, Inc. Names David Moore as Chief Commercial Officer to Manage Commercial Development and... Jan 07 2014
Cempra, Inc., Provides Update on Clinical Development of Solithromycin and Taksta(TM) Dec 16 2013
Cempra, Inc. to Host Solithromycin and TAKSTA Clinical Update Conference Call and Webcast Dec 16 2013

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK